Insights into the Implications of Coexisting Type 2 Inflammatory Diseases

References

• Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell. 2014;54:281–288. doi:10.1016/j.molcel.2014.03.030
   PubMed Web of Science ®Google Scholar
• Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135(3):626–635. doi:10.1016/j.jaci.2014.11.001
   PubMed Web of Science ®Google Scholar
• Caminati M, Pham DL, Bagnasco D, Canonica GW. Type 2 immunity in asthma. World Allergy Organ J. 2018;11:13. doi:10.1186/s40413-018-0192-5
   PubMed Web of Science ®Google Scholar
• Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S2–6. doi:10.1002/alr.21609
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol. 2015;15:57–65. doi:10.1038/nri3786
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395. doi:10.1164/rccm.200903-0392OC
   PubMed Web of Science ®Google Scholar
• Straumann A, Katzka DA. Diagnosis and treatment of eosinophilic esophagitis. Gastroenterology. 2018;154(2):346–359. doi:10.1053/j.gastro.2017.05.066
   PubMed Web of Science ®Google Scholar
• O’Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154(2):333–345. doi:10.1053/j.gastro.2017.06.065
   PubMed Web of Science ®Google Scholar
• Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol. 2008;6(2):165–173. doi:10.1016/j.cgh.2007.11.008
   PubMed Web of Science ®Google Scholar
• Remedios M, Campbell C, Jones DM, Kerlin P. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc. 2006;63:3–12. doi:10.1016/j.gie.2005.07.049
   PubMed Web of Science ®Google Scholar
• Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141:1593–1604. doi:10.1053/j.gastro.2011.07.044
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129:456–463.e453. doi:10.1016/j.jaci.2011.11.044
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59:21. doi:10.1136/gut.2009.178558
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a Phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158:111–122.e110. doi:10.1053/j.gastro.2019.09.042
   PubMed Web of Science ®Google Scholar
• Torres T, Ferreira EO, Gonçalo M, Mendes-Bastos P, Selores M, Filipe P. Update on Atopic Dermatitis. Acta Med Port. 2019;32:606–613. doi:10.20344/amp.11963
   PubMed Web of Science ®Google Scholar
• David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. In: Fortson EA, Feldman SR, Strowd LC, editors. Management of Atopic Dermatitis: Methods and Challenges. Cham: Springer International Publishing; 2017:21–37.
   Google Scholar
• Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403. doi:10.1016/j.alit.2016.12.002
   PubMed Web of Science ®Google Scholar
• Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11:213–739.
   PubMed Web of Science ®Google Scholar
• Schleimer RP. Immunopathogenesis of chronic rhinosinusitis and nasal polyposis. Annu Rev Pathol. 2017;12(1):331–357. doi:10.1146/annurev-pathol-052016-100401
   PubMedGoogle Scholar
• Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812–2820.e2813. doi:10.1016/j.jaip.2019.05.009
   PubMed Web of Science ®Google Scholar
• Schwartz JS, Tajudeen BA, Cohen NA. Medical management of chronic rhinosinusitis – a review of traditional and novel medical therapies. Expert Opin Investig Drugs. 2017;26(10):1123–1130. doi:10.1080/13543784.2017.1371699
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase 3 trials. The Lancet. 2019;394(10209):1638–1650. doi:10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Virchow JC. Eosinophilic esophagitis: asthma of the esophagus? Digestive Dis. 2014;32(1–2):54–60. doi:10.1159/000357010
   PubMed Web of Science ®Google Scholar
• Durrani SR, Mukkada VA, Guilbert TW. Eosinophilic esophagitis: an important comorbid condition of asthma? Clin Rev Allergy Immunol. 2018;55(1):56–64. doi:10.1007/s12016-018-8670-7
   PubMed Web of Science ®Google Scholar
• Mansoor E, Cooper GS. The 2010-2015 prevalence of eosinophilic esophagitis in the USA: a population-based study. Dig Dis Sci. 2016;61:2928–2934. doi:10.1007/s10620-016-4204-4
   PubMed Web of Science ®Google Scholar
• Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol. 2014;12:589–596.e581. doi:10.1016/j.cgh.2013.09.008
   PubMed Web of Science ®Google Scholar
• Maradey-Romero C, Prakash R, Lewis S, Perzynski A, Fass R. The 2011-2014 prevalence of eosinophilic oesophagitis in the elderly amongst 10 million patients in the United States. Aliment Pharmacol Ther. 2015;41(10):1016–1022. doi:10.1111/apt.13171
   PubMed Web of Science ®Google Scholar
• González-Cervera J, Arias Á, Redondo-González O, Cano-Mollinedo MM, Terreehorst I, Lucendo AJ. Association between atopic manifestations and eosinophilic esophagitis: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;118:582–590.e582. doi:10.1016/j.anai.2017.02.006
   PubMed Web of Science ®Google Scholar
• De Benedetto A, Kubo A, Beck LA. Skin barrier disruption: a requirement for allergen sensitization? J Invest Dermatol. 2012;132:949–963. doi:10.1038/jid.2011.435
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Iikura K, Morita H, Saito H. Barrier dysfunction in the atopic march—how does atopic dermatitis lead to asthma in children? J Allergy Clin Immunol. 2020;145:1551–1553. doi:10.1016/j.jaci.2020.04.014
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US Population-Based Study. Dermatitis. 2014;25:107.
   PubMed Web of Science ®Google Scholar
• Hua T, Silverberg JI. Atopic dermatitis in US adults: epidemiology, association with marital status, and atopy. Ann Allergy Asthma Immunol. 2018;121:622–624. doi:10.1016/j.anai.2018.07.019
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018;121:604–612.e603. doi:10.1016/j.anai.2018.07.042
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9:1133–1141.
   PubMed Web of Science ®Google Scholar
• Hakansson K, Bachert C, Konge L, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the United airways concept further supported. PLoS One. 2015;10:e0127228. doi:10.1371/journal.pone.0127228
   PubMed Web of Science ®Google Scholar
• Ragab A, Clement P, Vincken W. Objective assessment of lower airway involvement in chronic rhinosinusitis. Am J Rhinol. 2004;18:15–21. doi:10.1177/194589240401800105
   PubMedGoogle Scholar
• Bilodeau L, Boulay M-E, Prince P, Boisvert P, Boulet L-P. Comparative clinical and airway inflammatory features of asthmatics with or without polyps. Rhinology. 2010;48:420–425. doi:10.4193/Rhino09.095
   PubMed Web of Science ®Google Scholar
• McHugh T, Levin M, Snidvongs K, Banglawala SM, Sommer DD. Comorbidities associated with eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. Clin Otolaryngol. 2020;45:574–583. doi:10.1111/coa.13536
   PubMed Web of Science ®Google Scholar
• Joo MK, Park J-J, Kim S-H, et al. Prevalence and endoscopic features of eosinophilic esophagitis in patients with esophageal or upper gastrointestinal symptoms. J Dig Dis. 2012;13:296–303. doi:10.1111/j.1751-2980.2012.00589.x
   PubMed Web of Science ®Google Scholar
• Mulder DJ, Hurlbut DJ, Noble AJ, Justinich CJ. Clinical features distinguish eosinophilic and reflux-induced esophagitis. J Pediatr Gastroenterol Nutr. 2013;56:263–270.
   PubMed Web of Science ®Google Scholar
• Slae M, Persad R, Leung AJ-T, Gabr R, Brocks D, Huynh HQ. Role of environmental factors in the development of pediatric eosinophilic esophagitis. Dig Dis Sci. 2015;60:3364–3372. doi:10.1007/s10620-015-3740-7
   PubMed Web of Science ®Google Scholar
• Dellon ES, Rusin S, Gebhart JH, et al. A clinical prediction tool identifies cases of eosinophilic esophagitis without endoscopic biopsy: a prospective study. Am J Gastroenterol. 2015;110(9):1347–1354. doi:10.1038/ajg.2015.239
   PubMed Web of Science ®Google Scholar
• Doucet-Ladevèze R, Holvoet S, Raymond F, et al. Transcriptomic analysis links eosinophilic esophagitis and atopic dermatitis. Front Pediatr. 2019;7:467. doi:10.3389/fped.2019.00467
   PubMed Web of Science ®Google Scholar
• Padia R, Curtin K, Peterson K, Orlandi RR, Alt J. Eosinophilic esophagitis strongly linked to chronic rhinosinusitis. The Laryngoscope. 2016;126:1279–1283. doi:10.1002/lary.25798
   PubMed Web of Science ®Google Scholar
• Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131:1350–1360. doi:10.1016/j.jaci.2013.02.002
   PubMed Web of Science ®Google Scholar
• Chandra RK, Lin D, Tan B, et al. Chronic rhinosinusitis in the setting of other chronic inflammatory diseases. Am J Otolaryngol. 2011;32:388–391. doi:10.1016/j.amjoto.2010.07.013
   PubMed Web of Science ®Google Scholar
• Hirsch AG, Yan XS, Sundaresan AS, et al. Five-year risk of incident disease following a diagnosis of chronic rhinosinusitis. Allergy. 2015;70:1613–1621. doi:10.1111/all.12759
   PubMed Web of Science ®Google Scholar
• Rajan J, Newbury RO, Anilkumar A, Dohil R, Broide DH, Aceves SS. Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids. J Allergy Clin Immunol. 2016;137:147–156.e148. doi:10.1016/j.jaci.2015.05.045
   PubMed Web of Science ®Google Scholar
• Harer KN, Enders FT, Lim KG, Alexander JA, Katzka DA. An allergic phenotype and the use of steroid inhalers predict eosinophilic oesophagitis in patients with asthma. Aliment Pharmacol Ther. 2013;37:107–113. doi:10.1111/apt.12131
   PubMed Web of Science ®Google Scholar
• Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947. doi:10.1016/j.rmed.2020.105947
   PubMed Web of Science ®Google Scholar
• Zhang Z, Adappa ND, Doghramji LJ, et al. Quality of life improvement from sinus surgery in chronic rhinosinusitis patients with asthma and nasal polyps. Int Forum Allergy Rhinol. 2014;4:885–892. doi:10.1002/alr.21406
   PubMed Web of Science ®Google Scholar
• Schlosser RJ, Smith TL, Mace J, Soler ZM. Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy. 2017;72:483–491. doi:10.1111/all.13048
   PubMed Web of Science ®Google Scholar
• Stevens WW, Peters AT, Hirsch AG, et al. Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2017;5:1061–1070.e1063.
   PubMed Web of Science ®Google Scholar
• Casale T, Molfino NA, Silver J, et al. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Ann Allergy Asthma Immunol. 2021;S1081-1206(21)00382-3. doi:10.1016/j.anai.2021.05.021
   Web of Science ®Google Scholar
• Wollenberg A, Thomsen SF, Lacour J-P, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. doi:10.1016/j.waojou.2021.100519
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9:1212–1223.e1216.
   PubMed Web of Science ®Google Scholar
• Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: a review of present indications and uses out of indication. J Investig Allergol Clin Immunol. 2021;32:2.
   Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. doi:10.1111/all.14221
   PubMed Web of Science ®Google Scholar
• Clayton F, Fang JC, Gleich GJ, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147(3):602–609. doi:10.1053/j.gastro.2014.05.036
   PubMed Web of Science ®Google Scholar
• Loizou D, Enav B, Komlodi-Pasztor E, et al. A pilot study of omalizumab in eosinophilic esophagitis. PLoS One. 2015;10(3):e0113483. doi:10.1371/journal.pone.0113483
   PubMed Web of Science ®Google Scholar
• Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. JAMA Pediatr. 2020;174(1):29–37. doi:10.1001/jamapediatrics.2019.4476
   PubMed Web of Science ®Google Scholar
• Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8:990–998.
   PubMed Web of Science ®Google Scholar
• Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162(1):89–93. doi:10.1159/000350486
   PubMed Web of Science ®Google Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131:110–116.e111. doi:10.1016/j.jaci.2012.07.047
   PubMed Web of Science ®Google Scholar
• Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318–324. doi:10.4193/Rhino09.144
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi:10.1016/j.jaci.2020.05.032
   PubMed Web of Science ®Google Scholar
• Kang EG, Narayana PK, Pouliquen IJ, Lopez MC, Ferreira-Cornwell MC, Getsy JA. Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis. Allergy. 2020;75(4):950–953. doi:10.1111/all.14050
   PubMed Web of Science ®Google Scholar
• Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–995.e981–988. doi:10.1016/j.jaci.2011.07.056
   Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024–1031.e1014. doi:10.1016/j.jaci.2017.05.044
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133–1141. doi:10.1016/j.jaci.2006.05.031
   PubMed Web of Science ®Google Scholar
• NCT04543409. A study of benralizumab in patients with eosinophilic esophagitis (MESSINA); 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04543409?term=benralizumab&cond=eosinophilic+esophagitis&draw=2&rank=1. Accessed August 16, 2021.
   Google Scholar
• NCT04605094. Efficacy and safety study of the use of benralizumab for patients with moderate to severe atopic dermatitis; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04605094?term=benralizumab&cond=atopic+dermatitis&draw=2&rank=1. Accessed August 16, 2021.
   Google Scholar
• NCT03450083. Benralizumab effect on severe chronic rhinosinusitis with eosinophilic polyposis; 2021. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03450083?term=benralizumab&cond=chronic+rhinosinusitis&draw=2&rank=2. Accessed August 16, 2021.
   Google Scholar
• NCT04157335. Efficacy and safety study of benralizumab in patient with eosinophilic chronic rhinosinusitis with nasal polyps (ORCHID); 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04157335?term=benralizumab&cond=chronic+rhinosinusitis&draw=2&rank=3. Accessed August 16, 2021.
   Google Scholar
• Thaçi D, Simpson L, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266–275. doi:10.1016/j.jdermsci.2019.02.002
   PubMed Web of Science ®Google Scholar